BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023
02 Agosto 2023 - 8:00AM
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and
cell-derived therapeutics for the treatment of cardiovascular and
pulmonary diseases, today announced it will report its financial
results for the three and six months ended June 30, 2023 and
provide a corporate update by conference call on Wednesday, August
9, 2023 at 4:30 PM ET. Following management’s formal remarks, there
will be a question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10181574/fa1ff8fef0. Please note that
registered participants will receive their dial-in number upon
registration. For those who have not registered, to listen to the
call by phone, interested parties within the U.S. should call
1-833-316-0559 and international callers should call
1-412-317-5730. All callers should dial in approximately 10 minutes
prior to the scheduled start time and ask to be joined into the
BioCardia call. The conference call will also be available through
a live webcast, which can be accessed through the following link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=IBDjLUv7.
A webcast replay of the call will be available approximately one
hour after the end of the call through November 9, 2023 at the
above links. A telephonic replay of the call will be available
through August 23, 2023 and may be accessed by calling
1-877-344-7529 (domestic), 1-412-317-0088 (international) or
855-669-9658 (Canada) by using access code 7514640.
About BioCardia®BioCardia,
Inc., headquartered in Sunnyvale, California, is a developer
of two biotherapeutic platforms – the CardiAMP autologous bone
marrow derived mononuclear cell therapy for cardiovascular
indications, and the NK1R+ allogeneic bone marrow derived
mesenchymal stem cell therapies for cardiovascular and pulmonary
diseases. These platforms underly four product candidates, each
with the potential to meaningfully benefit millions of patients.
Three of these investigational therapies are enabled by the
Company’s proprietary biotherapeutic delivery platforms, which the
Company also selectively licenses to other biotherapeutic
development firms. For more information visit
www.biocardia.com.
MEDIA CONTACT:Miranda Peto, Marketing /
Investor Relations mpeto@biocardia.com (650) 226-0120
INVESTOR CONTACT:David McClung, Chief Financial
Officerinvestors@biocardia.com (650) 226-0120
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024